Nicolas Tilmans, Anagenex CEO

Seek­ing to 'close the loop' in drug dis­cov­ery with ma­chine learn­ing, Catalio-backed biotech emerges from se­mi-stealth

Two years af­ter se­cur­ing seed fund­ing and re­main­ing in a state of “se­mi-stealth,” a San Fran­cis­co biotech keen on com­bin­ing evo­lu­tion and small mol­e­cule dis­cov­ery re­cent­ly bagged a VC round that will let it do just that.

Known as An­a­genex, the com­pa­ny an­nounced Wednes­day that it raised a $30 mil­lion Se­ries A round, se­cur­ing the at­ten­tion of Catalio Cap­i­tal Man­age­ment as lead in­vestor. A few oth­er in­vestors tagged along, such as Lux Cap­i­tal and Khosla Ven­tures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.